Assessing Hepatitis B Reactivation Risk With Rituximab and Recent Intravenous Immunoglobulin Therapy-Reference-Cited by-同舟云学术

Assessing Hepatitis B Reactivation Risk With Rituximab and Recent Intravenous Immunoglobulin Therapy

Published:2020-03-01 Issue:3 Volume:7 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Dysart Claire¹,Rozenberg-Ben-Dror Karine²,Sales Mariscelle³

Affiliation:

1. Department of Veterans Affairs, Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin, USA

2. Department of Veterans Affairs, VISN 12 Great Lakes Healthcare System, Westchester, Illinois, USA

3. Department of Veterans Affairs Pharmacy Benefits Management Services and Center for Medication Safety (VA MedSAFE), Hines, Illinois, USA

Abstract

Abstract Hepatitis B reactivation (HBR) is a complication of immunosuppression associated with significant morbidity and mortality. To further complicate interpretation of hepatitis B serologies, false positivity can occur in patients with recent intravenous immunoglobulin exposure. This scenario is not well recognized and may lead to inappropriate prescribing of HBR prophylaxis.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofaa080/32757165/ofaa080.pdf

Reference12 articles.

1. New safety issues for hepatitis C antivirals;Institute for Safe Medication Practices (ISMP);ISMP Quarter Watch: Monitoring FDA MedWatch Reports January 25,2017

2. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions;Loomba;Gastroenterology,2017

3. Hepatitis B Virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update;Hwang;J Clin Oncol,2015

4. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy;Reddy;Gastroenterology,2015

5. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review;Liaw;Hepatology,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing hepatitis B virus serologies when transitioning patients from intravenous immune globulin therapy to rituximab for the treatment of autoimmune neuromuscular diseases;Muscle & Nerve;2024-09-12

2. 1-Minute Pearls/Pitfalls for the Clinician;Journal of Brown Hospital Medicine;2023-07-01

3. Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand;Medical Journal of Australia;2021-10-10

4. Analysis of Food Labels to Evaluate the Nutritional Quality of Bread Products and Substitutes Sold in Italy: Results from the Food Labelling of Italian Products (FLIP) Study;Foods;2020-12-20